Tony Friedman joins the Hatch-Waxman Litigation Team at The Simon Law Firm, P.C. Our team’s experience covers all aspects of the Hatch-Waxman Act, specializing in representing generic pharmaceutical companies in litigation concerning their Abbreviated New Drug Applications (ANDAs). In particular, we take a multi-disciplinary approach to our clients’ strategic and business objectives and efficiently focus on trial strategy, starting well before a court action is filed. We have found that thorough preparation and strategic planning is key to accelerating an ANDA case through the district courts in order to get our clients’ products to market as quickly and efficiently as possible. We are proud to offer alternative fee and value-based fee arrangements to our clients including deferred billing, contingent approaches, and flat fees. Please contact any member of our Hatch-Waxman Team for more information.